The Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine

In response to the SARS-CoV-2 Delta variant, which partially escaped the vaccine-induced immunity provided by two doses of vaccination with CoronaVac (Sinovac), the National Vaccine Committee recommended the heterologous CoronaVac-ChAdOx1 (Oxford–AstraZeneca), a prime–boost vaccine regimen. This pil...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Surakameth Mahasirimongkol, Athiwat Khunphon, Oraya Kwangsukstid, Sompong Sapsutthipas, Mingkwan Wichaidit, Archawin Rojanawiwat, Nuanjun Wichuckchinda, Wiroj Puangtubtim, Warangluk Pimpapai, Sakulrat Soonthorncharttrawat, Asawin Wanitchang, Anan Jongkaewwattana, Kanjana Srisutthisamphan, Daraka Phainupong, Naphatcha Thawong, Pundharika Piboonsiri, Waritta Sawaengdee, Thitiporn Somsaard, Kanokphon Ritthitham, Supaporn Chumpol, Nadthanan Pinyosukhee, Rattanawadee Wichajarn, Panadda Dhepakson, Sopon Iamsirithaworn, Supaporn Phumiamorn
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2022-03-01
Colecção:Vaccines
Assuntos:
homologous
heterologous
COVID-19 vaccine
heterologous prime-boost
immunogenicity
inactivated
Acesso em linha:https://www.mdpi.com/2076-393X/10/4/536
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados